Xia Zhang1, Ling Wang, Qing Shi. 1. Department of Respiratory Disease, No. 88 Hospital of PLA, Shangdong, Taian 271000. doctorzhangxia@163.com
Abstract
OBJECTIVE: To observe the effect of Fluticasone inhalation combined with Xiaoqinglong decoction (XQLD) on pulmonary function and serum interleukin-16 (IL-16) level in asthma patients. METHODS:Fifty-four mild or severe asthma patients were selected and randomly divided into three groups. The treated group was treated with Fluticasone inhalation combined with XQLD, Fluticasone group treated with Fluticasone inhalation, and XQLD group treated with XQLD respectively. Meanwhile ten healthy volunteers were selected as healthy control group. The conventional pulmonary functionFEV1 and respiratory impedance R5 were measured before and after 4 weeks treatment. The IL-16 levels were determined by using ELISA. RESULTS:FEV1 were obviously increased and R5 decreased in the three groups after treatment (P < 0.05 or P < 0.01), but the improvement was more significant in the treated group (P < 0.01). Before treatment, serum levels of IL-16 in all the three groups were significantly higher than those in the healthy control group (P < 0.01) and lowered after treatment respectively, the treated group was significantly lower than those of the other two groups (P < 0.05 or P < 0.01). The serum level of IL-16 was negatively correlated with FEV1 and positively with R5(r1 = -0.67, r2 = 0.71, P < 0.01). CONCLUSION: The effects of Fluticasone inhalation combined with XQLD on pulmonary function and serum IL-16 levels were superior to those of Fluticasone inhalation and XQLD alone in asthma patients. So it could become an important therapeutical method in treating mild and severe asthma patients.
RCT Entities:
OBJECTIVE: To observe the effect of Fluticasone inhalation combined with Xiaoqinglong decoction (XQLD) on pulmonary function and serum interleukin-16 (IL-16) level in asthmapatients. METHODS: Fifty-four mild or severe asthmapatients were selected and randomly divided into three groups. The treated group was treated with Fluticasone inhalation combined with XQLD, Fluticasone group treated with Fluticasone inhalation, and XQLD group treated with XQLD respectively. Meanwhile ten healthy volunteers were selected as healthy control group. The conventional pulmonary function FEV1 and respiratory impedance R5 were measured before and after 4 weeks treatment. The IL-16 levels were determined by using ELISA. RESULTS: FEV1 were obviously increased and R5 decreased in the three groups after treatment (P < 0.05 or P < 0.01), but the improvement was more significant in the treated group (P < 0.01). Before treatment, serum levels of IL-16 in all the three groups were significantly higher than those in the healthy control group (P < 0.01) and lowered after treatment respectively, the treated group was significantly lower than those of the other two groups (P < 0.05 or P < 0.01). The serum level of IL-16 was negatively correlated with FEV1 and positively with R5(r1 = -0.67, r2 = 0.71, P < 0.01). CONCLUSION: The effects of Fluticasone inhalation combined with XQLD on pulmonary function and serum IL-16 levels were superior to those of Fluticasone inhalation and XQLD alone in asthmapatients. So it could become an important therapeutical method in treating mild and severe asthmapatients.